S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)

Exclusion Criteria

• •Known or suspected allergy to any agent given in association with this trial
• •Local treatment within 4 weeks prior to start of study drug
• •History of any heart disease
• •History of HIV infection except for HBV and HCV
• •Active clinically serious infections (\> 2 NCI-CTC Version 3.0)
• •Clinically significant gastrointestinal bleeding within 4 weeks prior to study entry.
• •Embolization or infarction such as transient ischemic disease, deep vein thrombosis, pulmonary embolization within 6 months prior to study entry
• •Previous malignancy (except for cervical carcinoma in situ, adequate treated basal cell carcinoma, or superficial bladder tumors \[Ta, Tis and T1\], early gastric cancer, or other malignancies curatively treated \> 3 years prior to entry
• •Extrahepatic tumor spread which affects patient's prognosis, such as bony metastasis or brain metastasis
• •Hydrothorax， ascites and hydropericardium need to drain
• •Serious diarrhea
• •Combined with serious pulmonary diseases, such as interstitial pneumonia, pulmonary fibrosis and serious pulmonary emphysema
• •Serious complication,such as intestinal obstruction,renal insufficiency, hepatic insufficiency and cerebrovascular disorders
• •Pregnant or breast-feeding
• •Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment.
• •Gastrointestinal disease that may affect to the absorption of drug or pharmacokinetics.
• •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in this study
• •Patients unable to swallow oral medications.